PL374732A1 - Kompozycje farmaceutyczne jako inhibitory peptydazy dipeptydylowej IV (DPP-IV) - Google Patents
Kompozycje farmaceutyczne jako inhibitory peptydazy dipeptydylowej IV (DPP-IV)Info
- Publication number
- PL374732A1 PL374732A1 PL03374732A PL37473203A PL374732A1 PL 374732 A1 PL374732 A1 PL 374732A1 PL 03374732 A PL03374732 A PL 03374732A PL 37473203 A PL37473203 A PL 37473203A PL 374732 A1 PL374732 A1 PL 374732A1
- Authority
- PL
- Poland
- Prior art keywords
- dpp
- dipeptidyl peptidase
- inhibitors
- pharmaceutical compositions
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24683102A | 2002-09-19 | 2002-09-19 | |
US10/659,860 US20040121964A1 (en) | 2002-09-19 | 2003-09-11 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
Publications (1)
Publication Number | Publication Date |
---|---|
PL374732A1 true PL374732A1 (pl) | 2005-10-31 |
Family
ID=32033228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL03374732A PL374732A1 (pl) | 2002-09-19 | 2003-09-15 | Kompozycje farmaceutyczne jako inhibitory peptydazy dipeptydylowej IV (DPP-IV) |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1560811B9 (pl) |
JP (1) | JP4712387B2 (pl) |
KR (1) | KR101072236B1 (pl) |
CN (1) | CN101676264A (pl) |
AT (1) | ATE368647T1 (pl) |
AU (1) | AU2003282800B2 (pl) |
BR (1) | BR0314582A (pl) |
CA (2) | CA2497725C (pl) |
CY (1) | CY1110361T1 (pl) |
DE (1) | DE60315336T2 (pl) |
DK (1) | DK1560811T3 (pl) |
ES (1) | ES2290511T3 (pl) |
HK (1) | HK1082733A1 (pl) |
IL (1) | IL167434A (pl) |
MX (1) | MXPA05003091A (pl) |
NZ (1) | NZ538567A (pl) |
PL (1) | PL374732A1 (pl) |
PT (1) | PT1560811E (pl) |
TW (1) | TWI320406B (pl) |
WO (1) | WO2004026822A2 (pl) |
ZA (1) | ZA200502218B (pl) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1620091B1 (en) | 2003-05-05 | 2010-03-31 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
WO2005023762A1 (en) * | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
US7205409B2 (en) | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2005073186A1 (ja) * | 2004-01-29 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | ピロリジン誘導体 |
ES2375625T3 (es) | 2004-02-05 | 2012-03-02 | Kyorin Pharmaceutical Co., Ltd. | Derivados de biciclo éster. |
WO2005095339A1 (en) * | 2004-03-31 | 2005-10-13 | Pfizer Products Inc. | Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors |
CN1960990A (zh) * | 2004-05-18 | 2007-05-09 | 默克公司 | 作为用于治疗或预防糖尿病的二肽基肽酶-ⅳ抑制剂的环己基丙氨酸衍生物 |
CA2570047C (en) * | 2004-07-08 | 2010-09-28 | Warner-Lambert Company Llc | 4-cycloalkoxy benzonitriles as androgen modulators |
ATE553077T1 (de) * | 2004-07-23 | 2012-04-15 | Nuada Llc | Peptidaseinhibitoren |
WO2006011035A1 (en) * | 2004-07-23 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them |
JP4959569B2 (ja) | 2004-10-12 | 2012-06-27 | グレンマーク・ファーマシューティカルズ・エスエー | 新規なジペプチジルペプチダーゼiv阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス |
JP2008019168A (ja) * | 2004-10-22 | 2008-01-31 | Astellas Pharma Inc | 2−シアノ−4−フルオロピロリジン誘導体の製造法 |
EP1875921A1 (en) * | 2005-04-27 | 2008-01-09 | Ajinomoto Co., Inc. | Dpp4 inhibitor and pharmaceutical application thereof |
US20080300251A1 (en) * | 2005-09-05 | 2008-12-04 | Sattigeri Jitendra A | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors |
ME02005B (me) | 2005-09-14 | 2012-08-31 | Takeda Pharmaceuticals Co | Inhibitori dipeptidil peptidaze za lečenje dijabetesa |
CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
US7915427B2 (en) | 2006-03-08 | 2011-03-29 | Kyorin Pharmaceuticals Co., Ltd. | Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7985759B2 (en) * | 2006-04-03 | 2011-07-26 | Matrix Laboratories Ltd. | Dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them |
EP2007734A1 (en) | 2006-04-12 | 2008-12-31 | Probiodrug AG | Enzyme inhibitors |
EP2535338A1 (en) * | 2006-07-20 | 2012-12-19 | Abbott Laboratories | Synthesis of (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
EP2123636B1 (en) | 2007-03-22 | 2012-03-21 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
GB2465132B (en) | 2007-09-21 | 2012-06-06 | Lupin Ltd | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors |
CN102119139A (zh) | 2008-08-07 | 2011-07-06 | 杏林制药株式会社 | 二环[2.2.2]辛胺衍生物的制造方法 |
US8748457B2 (en) | 2009-06-18 | 2014-06-10 | Lupin Limited | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
WO2011112685A1 (en) * | 2010-03-10 | 2011-09-15 | Janssen Pharmaceutica Nv | 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (dpp-1) |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
CN102918027A (zh) | 2010-04-06 | 2013-02-06 | 艾尼纳制药公司 | Gpr119受体调节剂和对与所述受体有关的障碍的治疗 |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
TWI403716B (zh) * | 2010-08-13 | 2013-08-01 | Nat Univ Tsing Hua | 氫氣檢測器、系統及方法 |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
DK2686313T3 (en) | 2011-03-16 | 2016-05-02 | Probiodrug Ag | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
CN105601584A (zh) * | 2013-01-06 | 2016-05-25 | 天津市汉康医药生物技术有限公司 | 噻唑烷衍生物、其制备方法和用途 |
JP6590226B2 (ja) * | 2016-05-11 | 2019-10-16 | 株式会社シード探索研究所 | オキサアジリジン化合物およびその製造方法 |
CN109906082A (zh) * | 2016-09-07 | 2019-06-18 | 塔夫茨大学信托人 | 使用免疫dash抑制剂和pge2拮抗剂的组合治疗 |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2678938B1 (fr) * | 1991-07-10 | 1993-10-08 | Rhone Poulenc Rorer Sa | Derives de pyrrolidine, leur preparation et les medicaments les contenant. |
US5691356A (en) * | 1994-03-21 | 1997-11-25 | Bristol-Myers Squibb Company | Disubstituted heterocyclic thrombin inhibitors |
CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6172081B1 (en) * | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
TW583185B (en) * | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
-
2003
- 2003-09-15 JP JP2004537831A patent/JP4712387B2/ja not_active Expired - Fee Related
- 2003-09-15 EP EP03774478A patent/EP1560811B9/en not_active Expired - Lifetime
- 2003-09-15 AT AT03774478T patent/ATE368647T1/de active
- 2003-09-15 PL PL03374732A patent/PL374732A1/pl unknown
- 2003-09-15 MX MXPA05003091A patent/MXPA05003091A/es active IP Right Grant
- 2003-09-15 ES ES03774478T patent/ES2290511T3/es not_active Expired - Lifetime
- 2003-09-15 DE DE60315336T patent/DE60315336T2/de not_active Expired - Lifetime
- 2003-09-15 PT PT03774478T patent/PT1560811E/pt unknown
- 2003-09-15 KR KR1020057004773A patent/KR101072236B1/ko not_active IP Right Cessation
- 2003-09-15 BR BR0314582-4A patent/BR0314582A/pt not_active IP Right Cessation
- 2003-09-15 CA CA2497725A patent/CA2497725C/en not_active Expired - Fee Related
- 2003-09-15 AU AU2003282800A patent/AU2003282800B2/en not_active Ceased
- 2003-09-15 DK DK03774478T patent/DK1560811T3/da active
- 2003-09-15 CN CN200910166852A patent/CN101676264A/zh active Pending
- 2003-09-15 WO PCT/US2003/029018 patent/WO2004026822A2/en active IP Right Grant
- 2003-09-15 NZ NZ538567A patent/NZ538567A/en not_active IP Right Cessation
- 2003-09-15 CA CA2768674A patent/CA2768674A1/en not_active Abandoned
- 2003-09-19 TW TW092125921A patent/TWI320406B/zh not_active IP Right Cessation
-
2005
- 2005-02-16 ZA ZA2005/02218A patent/ZA200502218B/en unknown
- 2005-03-15 IL IL167434A patent/IL167434A/en not_active IP Right Cessation
-
2006
- 2006-02-09 HK HK06101745A patent/HK1082733A1/xx unknown
-
2007
- 2007-10-23 CY CY20071101364T patent/CY1110361T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE60315336T2 (de) | 2008-05-08 |
KR101072236B1 (ko) | 2011-10-12 |
HK1082733A1 (en) | 2006-06-16 |
KR20050043981A (ko) | 2005-05-11 |
TW200417545A (en) | 2004-09-16 |
DE60315336D1 (de) | 2007-09-13 |
ZA200502218B (en) | 2005-11-30 |
CA2497725A1 (en) | 2004-04-01 |
WO2004026822A3 (en) | 2004-05-06 |
IL167434A (en) | 2010-12-30 |
EP1560811A2 (en) | 2005-08-10 |
EP1560811B9 (en) | 2008-03-05 |
WO2004026822A2 (en) | 2004-04-01 |
MXPA05003091A (es) | 2005-05-27 |
TWI320406B (en) | 2010-02-11 |
JP2006503057A (ja) | 2006-01-26 |
AU2003282800A1 (en) | 2004-04-08 |
CY1110361T1 (el) | 2015-04-29 |
CN101676264A (zh) | 2010-03-24 |
JP4712387B2 (ja) | 2011-06-29 |
NZ538567A (en) | 2007-04-27 |
EP1560811B1 (en) | 2007-08-01 |
PT1560811E (pt) | 2007-11-14 |
DK1560811T3 (da) | 2007-12-10 |
CA2768674A1 (en) | 2004-04-01 |
ATE368647T1 (de) | 2007-08-15 |
ES2290511T3 (es) | 2008-02-16 |
BR0314582A (pt) | 2005-08-09 |
AU2003282800B2 (en) | 2009-10-29 |
CA2497725C (en) | 2012-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI320406B (en) | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) | |
WO2007027651A3 (en) | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) | |
YU34404A (sh) | N-supstituisani derivati pirolidina kao inhibitori dipeptidil-peptidaze iv | |
BR0315796A (pt) | Composto, composição farmacêutica, e, métodos para tratar diabetes, para tratar hiperglicemia, e para tratar obesidade em um mamìfero | |
HUP0303876A3 (en) | Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv | |
EP1406622A4 (en) | DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | |
EP1406872A4 (en) | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | |
EP1651623A4 (en) | HEXAHYDRODIAZEPINONES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OR PREVENTION OF DIABETES | |
EP1819674A4 (en) | FUSIONED AMINOPIPERIDINES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR TREATING OR PREVENTING DIABETES | |
WO2004050022A8 (en) | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
TNSN08367A1 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
WO2004037181A3 (en) | Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods | |
WO2006039325A3 (en) | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
WO2006127530A3 (en) | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
WO2004069162A3 (en) | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
WO2004103276A3 (en) | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
CL2004000437A1 (es) | Compuestos heterociclicos del tipo [1,4]-diazepan-2-ona sustituidos, inhibidores de la enzima dipeptidilpeptidasa-iv (cdp-iv); composicion farmaceutica; y su uso para preparar un medicamento para tratar hiperglucemia, diabetes tipo 2, obesidad, trast | |
WO2007136603A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
EP1490335A4 (en) | HETEROCYCLIC BETA-AMINO DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
ZA200806778B (en) | N-Hydroxyacrylamide compounds | |
HK1100559A1 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | |
DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
SG141430A1 (en) | Substituted pyrrole derivatives and their use as hmg-co inhibitors | |
PL374489A1 (pl) | Nowe podstawione kwasy aryloheksadienowe i ich estry, mające zastosowanie do leczenia i zapobiegania cukrzycy, dyslipidemii i miażdżycy tętnic, zawierające je kompozycje farmaceutyczne oraz sposoby ich otrzymywania | |
TW200500338A (en) | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |